TICKERNERD
Menu
ARCTARCTHealthcare · Biotechnology

ARCT Stock Forecast: Arcturus Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$6.00
+4.17% on the day

The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. hold a median 12-month price target of $21 — +241.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$170.5M
Ticker Nerd rank
44 / 100
Median analyst target
$21
Analysts covering
13
Total return, dividends reinvested
1W
+4.2%
1M
−17.6%
YTD
−2.1%
1Y
−51.2%
From 52W high
−74.1%
From 52W low
+8.5%
$6
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arcturus Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
80
Accruals
78
Quality
71
Size
70
Revisions
55
Volatility
34
Value
22
Growth
18
Momentum
10

Issuance (80): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (10): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Arcturus Therapeutics Holdings, Inc. — and when they’d sell — is the membership.

Wall Street

ARCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26ARCTHigh $40Median $21Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
10 Buy3 Hold0 Sell
Low $8Median $21High $40

The green dot is the last close — the median target sits +241.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 July 2026Freedom BrokerInitiatesBuy$27
18 Mar 2026B. Riley SecuritiesInitiatesBuy—
5 Mar 2026CitigroupMaintainsBuy—
4 Mar 2026CitigroupMaintainsNeutral—
4 Mar 2026Piper SandlerMaintainsOverweight—
6 Jan 2026CitigroupMaintainsNeutral—
13 Nov 2025CitigroupMaintainsNeutral—
11 Nov 2025HC Wainwright & Co.MaintainsNeutral—
11 Nov 2025Piper SandlerMaintainsOverweight—
24 Oct 2025HC Wainwright & Co.DowngradeNeutral—
23 Oct 2025CitigroupDowngradeNeutral—
23 Oct 2025GuggenheimDowngradeNeutral—
23 Oct 2025Wells FargoMaintainsOverweight—
22 Oct 2025BTIGMaintainsBuy—
22 Oct 2025GuggenheimDowngradeNeutral—
4 Sept 2025HC Wainwright & Co.AssumesBuy$60
22 Aug 2025Leerink PartnersMaintainsOutperform—
12 Aug 2025CitigroupMaintainsBuy—
12 Aug 2025Wells FargoMaintainsOverweight—
2 July 2025ScotiabankMaintainsSector Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ARCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
5
Fundamentals

Arcturus Therapeutics Holdings, Inc. (ARCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
10.1×

Cheaper than 59% of US stocks

Price / sales
3.1×

Cheaper than 40% of US stocks

Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
0.3×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−93.0%

Higher than 2% of US stocks

Earnings growth (YoY)
−97.6%

Higher than 2% of US stocks

Gross margin
—
Operating margin
−1403.7%

Higher than 5% of US stocks

Net margin
−143.8%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−37.0%

Higher than 25% of US stocks

Return on assets
−19.1%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARCTArcturus Therapeutics Holdings, Inc.$170.5M
44
ALECAlector, Inc.$164.8M
45
PYXSPyxis Oncology, Inc.$165.0M
90
LENZLENZ Therapeutics, Inc.$165.8M
17
CRBPCorbus Pharmaceuticals Holdings, Inc.$166.2M
33
ARMPArmata Pharmaceuticals, Inc.$166.3M
69
ORMPOramed Pharmaceuticals, Inc.$166.9M
76
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ARCT news & analysis

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

Business Wire · 28 July 2026neutral

Arcturus Therapeutics announced it will release its second quarter 2026 financial results after market close on August 6, 2026, and will host a conference call and webcast at 4:30 pm Eastern Time that same day.

Why it matters — The earnings release and conference call will provide ARCT shareholders with the company's latest financial performance and any corporate updates.

FAQ

Frequently asked questions about ARCT stock

What is the ARCT stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. have a median 12-month price target of $21, with estimates ranging from $8 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARCT stock a buy right now?

Of the 13 analysts covering Arcturus Therapeutics Holdings, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcturus Therapeutics Holdings, Inc. 44 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARCT?

As at 1 Aug 2026, Arcturus Therapeutics Holdings, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (80 of 100).

Will ARCT stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +241.7% from the last close, and Ticker Nerd's factor model ranks Arcturus Therapeutics Holdings, Inc. 44 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARCT stock forecast for 2030?

No analyst covering Arcturus Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $40 over the next 12 months.

How has ARCT stock performed over the past year?

Arcturus Therapeutics Holdings, Inc. returned -51.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arcturus Therapeutics Holdings, Inc. do?

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines.

What is the latest news on ARCT?

The most recent item we track (Business Wire, 28 July 2026): "Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026". Arcturus Therapeutics announced it will release its second quarter 2026 financial results after market close on August 6, 2026, and will host a conference call and webcast at 4:30 pm Eastern Time that same day.

Company

About Arcturus Therapeutics Holdings, Inc.

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines. It leverages proprietary LUNAR lipid-mediated delivery and STARR self-amplifying mRNA platforms to advance its pipeline. Key internal programs include ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032, an inhaled mRNA therapy for cystic fibrosis, both in Phase 2 clinical studies targeting severe patient populations. In vaccines, it partners with CSL Seqirus on mRNA candidates for COVID-19, influenza, and other infectious diseases, with KOSTAIVE approved in Japan, the EU, and the UK, generating initial commercial sales through collaborators like Meiji and CSL Seqirus. The company operates in a single business segment encompassing discovery, development, and commercialization of mRNA medicines. Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a significant role in the biotech sector by pioneering mRNA technologies for rare diseases and partnered vaccine franchises.

CEO Mr. Joseph E. Payne M.Sc. · 106 employees · United States · https://arcturusrx.com